The Furiex Team
Furiex has assembled a world-class team of drug development experts, bringing extensive experience across a wide range of therapeutic areas. Our leadership team collectively has more than 75 years of experience. Together, we build value by designing innovative programs that drive development faster and more efficiently across the development timeline.
Preclinical and Clinical OperationsTOP
-
June Almenoff, M.D., Ph.D., FACP
President and Chief Medical Officer
Dr. June Almenoff has more than 12 years of industry experience as a senior executive with a large pharmaceutical company. She brings extensive expertise in clinical safety and pharmacovigilance and has managed a diverse therapeutic portfolio. Dr. Almenoff previously served on the Duke University Medical Center faculty and conducted medical research.
More -
Senior Vice President, Clinical Development and Operations
Dr. Paul Covington brings more than 17 years of drug development experience overseeing all aspects of medical and regulatory affairs including pharmacovigilance, medical writing and program management. Dr. Covington also has experience as a medical practitioner in both hospital and private practice settings.
More -
Gail McIntyre, Ph.D., CH (ASCP), DABT
Senior Vice President, Research
Dr. Gail McIntyre has more than 19 years of experience in the drug discovery and development industry at both biotechnology and pharmaceutical companies. She is a board certified toxicologist with extensive experience in moving compounds through the lead optimization phase to IND. Dr. McIntyre led PPD’s compound partnering group for six years.
More -
Executive Director, Regulatory Affairs
Ms. Michelle Usher has more than 22 years of experience in drug development, with the past 17 in regulatory affairs. Ms. Usher’s experience covers numerous therapeutic areas including metabolic/endocrine, oncology and analgesics. She has authored and/or managed more than 75 regulatory submissions and has extensive CMC expertise.
More -
Executive Director, Clinical Operations
Ms. Lisa Liverman has more than 19 years of clinical project management in the area of general medicine. Her main therapeutic experience is in diabetes and associated complications, obesity, erectile dysfunction, hypertension, hypercholesterolemia and multiple sclerosis.
More -
Executive Director, Clinical Pharmacology and Biostatistics
Dr. Michael Davenport brings more than 25 years of drug research development and manufacturing experience for both small and large pharmaceutical companies. He provides development strategies and pharmacokinetic support in interpretation of data.
More -
Senior Director, Clinical Operations
Dr. Scott Dove has more than 15 years of experience in drug development, including preclinical pharmacology assessments in the laboratory setting and in clinical development efforts. His main areas of expertise include medical writing, product development and project management.
More -
Senior Director, Chemistry
Dr. Tim Costello brings more than 20 years of industrial chemistry experience in pharmaceutical development. His areas of expertise include organic and analytical chemistry, from small scale through pilot plant scale, and solid-state chemistry development as it applies to preformulation and formulation development.
More -
Associate Director, Preclinical Development
Dr. Rocio Lopez has more than seven years of experience as a preclinical toxicologist assessing small molecules, biologics and medical devices. Her main areas of expertise include early development and clinical pharmacology in hematology, oncology, infectious diseases, inflammatory diseases and dermatology.
More -
Associate Director, Preclinical Development
Mr. David Prohaska has more than 12 years of experience in all aspects of preclinical drug development. His experience includes pharmacokinetic study coordination and preclinical project manager.
More
Strategic Development, Finance and LegalTOP
-
Vice President, Strategic Development
Mr. Sailash Patel has more than 10 years of experience in the pharmaceutical industry. His wide-ranging business experience includes corporate strategic planning, mergers and acquisitions, and therapeutic strategic alliance business development. Mr. Patel has supported transactions with an aggregate value in excess of $800 million.
More -
Vice President, Legal Affairs and Secretary
Dr. Nadine Chien has more than 11 years of experience in intellectual property, licensing and other transactional work. She has extensive experience negotiating and managing strategic alliances. Her areas of scientific expertise include molecular and cellular biology, genomics and biochemistry.
More -
Chief Financial Officer, Treasurer and Assistant Secretary
Mr. Marshall Woodworth has 14 years of experience in the biopharmaceutical industry, including various positions at Eli Lilly and Company. At Furiex, he is responsible for finance, accounting, human resources and purchasing.
More